Genelux Corporation
GNLX
NASDAQ·Healthcare·Biotechnology·Mkt cap $109.4M
$2.44
▼ -3.17%
P/E
-2.74
Mkt Cap
$109.4M
52-Wk Range
$2.29–$8.54
52-Week Range
$2.29 - $8.54
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 31.5% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary modified vaccinia virus platform with established safety profile
- Differentiated oncolytic viral immunotherapy approach with limited direct competition
- Multiple cancer indications in development pipeline reducing single-asset risk
- Experienced management team and scientific advisory board in oncology and virology
Bear Case
1 risk
- Low volatility (beta 0.6).
Growth
Stable outlook
Clinical trial advancement and regulatory approval of Olvi-Vec for ovarian and lung cancer
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Weak
-16.7% over 3m
Quality
Below
Below average quality
Dividend
None
No dividend
Smart-money signal
Who's buying GNLX right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 4, 2026
AUG 13, 2026
Reported EPS of -$0.21 vs -$0.20 consensus (-6.8% surprise).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-6.8%
Revenue trend · last 8Q
—
—
-100%
—
—
—
—
—
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$0
$0
$0
$0
$0
$8.0K
$0
$0
Margins · last 8Q
Profit
—
Wall Street consensus
1 analyst · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Benchmark · Mar 20, 2026
vs Industry
How GNLX stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related